Characteristics of ML-DS 2006 and AML-BFM 98 (ML-DS) patients
| . | ML-DS 2006 . | AML BFM 98 . | |||
|---|---|---|---|---|---|
| N . | % . | N . | % . | P . | |
| Total | 170 | 100 | 67 | 100 | |
| Sex | .475 | ||||
| Male | 85 | 50 | 30 | 44.8 | |
| Female | 85 | 50 | 37 | 55.2 | |
| FAB | .016* | ||||
| M0 | 4 | 2.8 | 6 | 9.1 | |
| M1/M2 | — | — | — | — | |
| M3 | — | — | — | — | |
| M4/M5 | — | — | 1 | 1.5 | |
| M6 | 1 | 0.8 | 1 | 1.5 | |
| M7 | 124 | 96.9 | 58 | 87.9 | |
| Other | — | — | — | — | |
| Age, y | .788 | ||||
| <1 | 24 | 14.1 | 12 | 17.9 | |
| 1 | 88 | 51.8 | 36 | 53.7 | |
| 2 | 43 | 25.30 | 15 | 22.4 | |
| 3 | 10 | 5.9 | 3 | 4.5 | |
| 4 | 3 | 1.8 | — | — | |
| ≥5 | 2 | 1.2 | 1 | 1.5 | |
| WBC, 109/L | .014* | ||||
| <10 | 144 | 87.3 | 47 | 70.1 | |
| 10-20 | 13 | 7.9 | 13 | 19.4 | |
| 20-50 | 4 | 2.4 | 4 | 6 | |
| ≥50 | 4 | 2.4 | 3 | 4.5 | |
| BM blasts, % | <.001* | ||||
| <20 | 74 | 47.1 | 12 | 18.2 | |
| ≥20 | 83 | 52.9 | 54 | 81.8 | |
| CNS involvement | |||||
| No | 136 | 100 | 64 | 100 | |
| Yes | — | — | — | — | |
| Organ involvement | .227 | ||||
| No | 166 | 97.6 | 63 | 94 | |
| Yes | 4 | 2.4 | 4 | 6 | |
| Case history, wk | .094 | ||||
| <3 | 49 | 52.7 | 22 | 37.9 | |
| ≥3 | 44 | 47.3 | 36 | 62.1 | |
| TAM history | .007 | ||||
| No | 80 | 65 | 56 | 83.6 | |
| Yes | 43 | 35 | 11 | 16.4 | |
| GATA1 | |||||
| WT | 17 | 14.8 | |||
| Mutated | 98 | 85.2 | |||
| Therapy response | |||||
| Early death | 2 | 1.2 | — | — | |
| NR/PR | — | — | — | — | |
| Relapse | 9 | 5.3 | 4 | 6 | |
| Death in CCR | 5 | 2.9 | 4 | 6 | |
| Secondary malignancy | 3 | 1.8 | 1 | 1.5 | |
| LTFU in CCR | 7 | 4.1 | 4 | 6 | |
| CCR | 144 | 84.7 | 54 | 80.6 | |
| Median | |||||
| Age, y | 1.6 | 1.76 | .752 | ||
| WBC, 109/L | 5.1 | 6.6 | .017* | ||
| Hemoglobin, g/dL | 9.3 | 8.6 | .033* | ||
| BM blasts, % | 20 | 29 | <.001* | ||
| Follow-up, y | 4.0 | 9.6 | |||
| . | ML-DS 2006 . | AML BFM 98 . | |||
|---|---|---|---|---|---|
| N . | % . | N . | % . | P . | |
| Total | 170 | 100 | 67 | 100 | |
| Sex | .475 | ||||
| Male | 85 | 50 | 30 | 44.8 | |
| Female | 85 | 50 | 37 | 55.2 | |
| FAB | .016* | ||||
| M0 | 4 | 2.8 | 6 | 9.1 | |
| M1/M2 | — | — | — | — | |
| M3 | — | — | — | — | |
| M4/M5 | — | — | 1 | 1.5 | |
| M6 | 1 | 0.8 | 1 | 1.5 | |
| M7 | 124 | 96.9 | 58 | 87.9 | |
| Other | — | — | — | — | |
| Age, y | .788 | ||||
| <1 | 24 | 14.1 | 12 | 17.9 | |
| 1 | 88 | 51.8 | 36 | 53.7 | |
| 2 | 43 | 25.30 | 15 | 22.4 | |
| 3 | 10 | 5.9 | 3 | 4.5 | |
| 4 | 3 | 1.8 | — | — | |
| ≥5 | 2 | 1.2 | 1 | 1.5 | |
| WBC, 109/L | .014* | ||||
| <10 | 144 | 87.3 | 47 | 70.1 | |
| 10-20 | 13 | 7.9 | 13 | 19.4 | |
| 20-50 | 4 | 2.4 | 4 | 6 | |
| ≥50 | 4 | 2.4 | 3 | 4.5 | |
| BM blasts, % | <.001* | ||||
| <20 | 74 | 47.1 | 12 | 18.2 | |
| ≥20 | 83 | 52.9 | 54 | 81.8 | |
| CNS involvement | |||||
| No | 136 | 100 | 64 | 100 | |
| Yes | — | — | — | — | |
| Organ involvement | .227 | ||||
| No | 166 | 97.6 | 63 | 94 | |
| Yes | 4 | 2.4 | 4 | 6 | |
| Case history, wk | .094 | ||||
| <3 | 49 | 52.7 | 22 | 37.9 | |
| ≥3 | 44 | 47.3 | 36 | 62.1 | |
| TAM history | .007 | ||||
| No | 80 | 65 | 56 | 83.6 | |
| Yes | 43 | 35 | 11 | 16.4 | |
| GATA1 | |||||
| WT | 17 | 14.8 | |||
| Mutated | 98 | 85.2 | |||
| Therapy response | |||||
| Early death | 2 | 1.2 | — | — | |
| NR/PR | — | — | — | — | |
| Relapse | 9 | 5.3 | 4 | 6 | |
| Death in CCR | 5 | 2.9 | 4 | 6 | |
| Secondary malignancy | 3 | 1.8 | 1 | 1.5 | |
| LTFU in CCR | 7 | 4.1 | 4 | 6 | |
| CCR | 144 | 84.7 | 54 | 80.6 | |
| Median | |||||
| Age, y | 1.6 | 1.76 | .752 | ||
| WBC, 109/L | 5.1 | 6.6 | .017* | ||
| Hemoglobin, g/dL | 9.3 | 8.6 | .033* | ||
| BM blasts, % | 20 | 29 | <.001* | ||
| Follow-up, y | 4.0 | 9.6 | |||
—, none; CCR, complete continuous remission; LTFU, lost to follow-up; PR, partial response; WT, wild type.
Bold P values are significant (<.05).